Journal
CLINICAL AND VACCINE IMMUNOLOGY
Volume 18, Issue 5, Pages 885-887Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/CVI.00358-10
Keywords
-
Categories
Funding
- Crucell Switzerland AG ( Berne, Switzerland)
Ask authors/readers for more resources
Boosting adult travelers with the virosome-formulated, aluminum-free hepatitis A vaccine Epaxal up to 128 months after a single primary dose confers full protection against hepatitis A, even in travelers aged 50 years and above. Delaying the booster dose did not influence the immune memory response to Epaxal.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
